Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 19/20 | 0.69 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.67 |
| ▸ | KCNN1 | Q92952 | 1/20 | 0.41 |
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.41 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL897173 | 1.00 | PDE10A (0.69) | PDE10ANR1I2CYP2C9KCNN1KCNN2 | |
| SCHEMBL10085529 | 0.87 | PDE10A (0.79) | PDE10ANR1I2CYP2C9CYP3A4 | |
| SCHEMBL900313 | 0.87 | PDE10A (0.76) | PDE10ANR1I2CYP2C9 | |
| SCHEMBL14974283 | 0.87 | PDE10A (0.76) | PDE10ANR1I2CYP2C9 | |
| SCHEMBL14973870 | 0.87 | PDE10A (0.76) | PDE10ANR1I2CYP2C9 | |
| SCHEMBL14973950 | 0.83 | PDE10A (0.77) | PDE10ANR1I2CYP2C9 | |
| SCHEMBL14973951 | 0.83 | PDE10A (0.77) | PDE10ANR1I2CYP2C9 | |
| SCHEMBL14974076 | 0.83 | PDE10A (0.74) | PDE10ANR1I2CYP2C9 | |
| Fumaric Acid SCHEMBL14973853 | 0.83 | PDE10A (0.67) | PDE10ANR1I2CYP2C9 | |
| Fumaric Acid SCHEMBL14973856 | 0.83 | PDE10A (0.67) | PDE10ANR1I2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2621926-B1 | PYRAZOLOPYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME (US) | 2017-08-30 | — | — | EP | disclosed |
| US-8957077-B2 | Pyrazolopyrimidine PDE 10 inhibitors | MERCK SHARP & DOHME CORP. (US) | 2015-02-17 | — | — | US | disclosed |
| EP-2621926-A2 | PYRAZOLOPYRIMIDINE PDE10 INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-08-07 | — | — | EP | disclosed |
| US-20130137707-A1 | PYRAZOLOPYRIMIDINE PDE 10 INHIBITORS | MERCK SHARP & DOHME LLC | 2013-05-30 | — | — | US | disclosed |
| WO-2012044562-A2 | PYRAZOLOPYRIMIDINE PDE10 INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2012-04-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137707-A1 | PYRAZOLOPYRIMIDINE PDE 10 INHIBITORS | PDE12, PDE5A, PDE4A | PDE10A 4/4885NR1I2 3377/4885CYP2C9 1687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.